Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Natera Inc
(NQ:
NTRA
)
167.26
-2.10 (-1.24%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Natera Inc
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Natera to Present New Data from the CIRCULATE-Japan and BESPOKE CRC Studies at ASCO GI 2024 Supporting Signatera’s Clinical Utility in CRC
January 18, 2024
From
Natera, Inc.
Via
Business Wire
Expert Ratings For Natera
January 17, 2024
Via
Benzinga
Natera Hits A Nearly Two-Year High After Notching A Win In A Patent Battle
January 17, 2024
The company must pay $57 million in damages, but that's far less than expected.
Via
Investor's Business Daily
Topics
Intellectual Property
Exposures
Intellectual Property
Why DatChat Shares Are Trading Lower By Around 33%; Here Are 20 Stocks Moving Premarket
January 17, 2024
Shares of DatChat, Inc. (NASDAQ: DATS) fell sharply in pre-market trading after announcing a proposed underwritten public offering of common stock. DatChat shares dipped 33.1% to $2.13 in pre-market...
Via
Benzinga
Natera Inc. (NASDAQ: NTRA) Records 52-Week High Tuesday Morning
January 09, 2024
Via
Investor Brand Network
The Analyst Landscape: 8 Takes On Natera
December 29, 2023
Via
Benzinga
The Latest Analyst Ratings for Natera
December 12, 2023
Via
Benzinga
Progress Software Posts Strong Q4 Results, Joins Impinj, REGENXBIO And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session
January 17, 2024
U.S. stock futures were lower this morning, with the Dow Jones futures falling more than 100 points on Wednesday. Shares of Progress Software Corporation (NASDAQ: PRGS) rose in pre-market trading as...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Natera Provides Update on Ravgen Trial
January 16, 2024
From
Natera, Inc.
Via
Business Wire
Bull of the Day - NeoGenomics
January 12, 2024
But in late December, shares took a big hit on patent litigation with competitor Natera. Let's review the primary commercial business of NEO and then that will help put the legal news into context.
Via
Talk Markets
Topics
Intellectual Property
Exposures
Intellectual Property
Natera Announces Preliminary Fourth Quarter and Full Year 2023 Revenues
January 09, 2024
From
Natera, Inc.
Via
Business Wire
Analyst Expectations for Natera's Future
November 09, 2023
Via
Benzinga
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
December 29, 2023
Each week, Benzinga's Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the surface and warrant attention.
Via
Benzinga
Expedia To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Friday
December 29, 2023
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
Natera to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
December 29, 2023
From
Natera, Inc.
Via
Business Wire
US Court Prohibits NeoGenomics To Sell Type Of Diagnostic Kits To Detect Smaller Number Of Cancer Cells, Favoring Natera In Lawsuit
December 28, 2023
Shares of NeoGenomics Inc (NASDAQ: NEO) fell Thursday after the company received a preliminary injunction from a North Carolina district court, which prohibits the company from
Via
Benzinga
Natera Wins Preliminary Injunction in Patent Infringement Lawsuit Against NeoGenomics’ RaDaR Test
December 27, 2023
From
Natera, Inc.
Via
Business Wire
NATERA ALERT: Bragar Eagel & Squire, P.C. is Investigating Natera, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
December 26, 2023
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
Natera Announces New Study Highlighting the Benefits of Signatera’s Unique Method of Quantifying ctDNA
December 21, 2023
From
Natera, Inc.
Via
Business Wire
Delaware Court Denies CareDx’s Motion for Summary Judgment on Two Natera Patents
December 11, 2023
From
Natera, Inc.
Via
Business Wire
Natera Presents New Signatera™ MRD Data Across Breast Cancer Treatment Settings at SABCS 2023
December 06, 2023
From
Natera, Inc.
Via
Business Wire
Top 5 Health Care Stocks That May Collapse In November
November 17, 2023
As of Nov. 17, 2023, five stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Via
Benzinga
Natera Announces Real-World Data Collaboration with Merck
November 14, 2023
From
Natera, Inc.
Via
Business Wire
Disney, Twilio, TransDigm, Marathon Digital And Other Big Stocks Moving Higher On Thursday
November 09, 2023
U.S. stocks traded mostly lower, with the Dow Jones falling around 75 points on Thursday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Natera Reports Third Quarter 2023 Financial Results
November 08, 2023
From
Natera, Inc.
Via
Business Wire
Natera Announces Randomized, Phase III TREAT ctDNA Trial in Early-Stage Breast Cancer
November 08, 2023
From
Natera, Inc.
Via
Business Wire
Natera to Participate in November Investor Conferences
November 07, 2023
From
Natera, Inc.
Via
Business Wire
NATERA INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Natera, Inc. - NTRA
November 03, 2023
From
Kahn Swick & Foti, LLC
Via
Business Wire
Natera’s Landmark RenaCARE Study Demonstrates Significant Diagnostic and Clinical Utility of Renasight™ in Chronic Kidney Disease
November 02, 2023
From
Natera, Inc.
Via
Business Wire
Bull Of The Day: NeoGenomics
October 24, 2023
NeoGenomics is a small-cap provider of cancer genetics diagnostics. They boast one of the most comprehensive oncology-focused testing menus in the world to help physicians diagnose and treat cancer.
Via
Talk Markets
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.